LiteFold use cases

See how research and R&D teams use LiteFold to design, analyze and de-risk therapeutics, from first hypothesis to IND.

• Rare Disease Variant Interpretation: Interpret rare disease variants faster with literature, population, and structural evidence in one place.
• Hypothesis Generation: Generate and rank research hypotheses backed by literature, variant, and structural evidence.
• Analytical Comparability Planning: Plan comparability studies and flag critical quality attributes before you touch the bench.
• Biosimilarity Assessment: Build a defensible biosimilarity case grounded in regulatory guidance and analytical evidence.
• Cell Culture Process Optimization: Diagnose process deviations and design the next experiment to close the gap faster.
• Process Characterization Study Design: Design statistically sound characterization studies and identify your critical process parameters.
• Formulation Development Advisor: Select excipients and forecast stability to converge on a robust formulation faster.
• Patent Analysis: Map the patent landscape, assess freedom to operate, and surface white-space opportunities.
• Lead Optimization: Rank candidates by binding quality, resistance coverage, and ADMET before you synthesize.
• Preclinical to IND: Organize pharmacology, toxicology, and CMC evidence into an IND-ready development package.
• Experimental Protocol Generation & Optimization: Generate a complete purification SOP with CPPs, CQAs, and a scale-up strategy built in.
• Clinical Trial Development: Design randomized trial protocols with biomarker-driven endpoints and eligibility criteria.
• Bioprocess Scale up Strategy: Optimize media, feeding strategy, and CPPs to scale production without losing quality.
• Docking Campaign and Design Interpretation: Rank experimental vs. AI-predicted binding models to identify the most reliable complex.
• Molecular Dynamics Simulation & Stability Analysis: Validate protein–ligand binding stability with RMSD, RMSF, and contact persistence over a full MD trajectory.
• Analytical Comparability Package for a Biosimilar Monoclonal Antibody: A structural, impurity, and stability comparability dossier with a three-tier statistical similarity framework, aligned to FDA, EMA, and WHO biosimilar guidance.
• Comprehensive Biosimilarity Assessment Strategy: An end-to-end biosimilarity assessment spanning reference product characterization, analytical and functional comparability, immunogenicity risk, and indication extrapolation.
• Formulation Development Strategy for a High-Concentration Biosimilar: A QTPP, formulation strategy, stability program, and risk-based development plan for a high-concentration antibody intended for prefilled syringe or autoinjector delivery.
• Glycosylation Comparability Assessment of a Biosimilar Candidate: A tiered statistical equivalence framework comparing glycoform distributions, functional impact, and immunogenicity risk between a biosimilar candidate and its reference product.
• Technical Investigation into Protein A Chromatography Yield Decline: A fishbone and ranked FMEA analysis of a progressive Protein A step-yield decline across commercial batches, with confirmatory experiments and CAPA recommendations.
• Process Characterization Study for a Protein A Capture Step: A characterization study linking critical process parameters to critical quality attributes for a commercial-scale Protein A affinity chromatography step.
• CMC Scale-Up Strategy for Upstream Bioreactor Manufacturing: The engineering and QbD-based justification for a large bioreactor volume scale-up, including FMEA risk assessment and a comparability testing plan.
• Upstream Process Optimization Strategy for Fed-Batch Cell Culture: A prioritized, risk-ranked set of interventions spanning feeding strategy, temperature shift, and media supplementation to improve titer and quality attributes.
• Comprehensive CMC Development Strategy for a Monoclonal Antibody Biosimilar: An integrated CMC strategy spanning cell line development, upstream and downstream process design, formulation, analytical comparability, and scale-up across dual filing pathways.
• Structural Analysis of an Antibody-Receptor Interaction via Docking: A comparison of an experimental antibody-antigen co-crystal structure against an ab initio cofolding prediction, validating interface residues and binding accuracy.